Skip to content

AI Tools Earnings Screener Charts Watchlist

Connect your AI

Stocks
ALN
Alnylam Pharmaceuticals
Business Segments
Business Segments
R&D

R&D

Alnylam Pharmaceuticals·Business Segments·1 segment·Rolls up to R&D

Breakdown

Segments

Business SegmentsView metric

Explore

Earnings Calendar
Stock Screener
Metrics Screener
Charts
AI Tools
Watchlist

Resources

Pricing
Releases
About
Contact
Methodology
Cite & Reuse
Sign in / Sign up

Connect

Claude
Claude Code
ChatGPT
Codex
Codex CLI
Cursor
Other clients

Legal

Privacy Policy
Terms of Service
Cookie Policy
SEC EDGAR
support@opencapital.sh

© 2026 OpenCapital. All rights reserved.

Data sourced from SEC filings — methodology

OpenCapital is not affiliated with or endorsed by the U.S. Securities and Exchange Commission (SEC). All data is sourced from publicly available SEC filings.

Segment	Q2 '26
Business Segments	$413.13M
Total	$413.13M